Investing.com - Financial Markets Worldwide
Get 40% Off
Get 40% Off
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list

BioNTech SE (BNTX)

NASDAQ
Symbol
Exchange
Currency
BNTXNASDAQUSD
BNTXNBIVAMXN
22UAyXetraEUR
22UAyFrankfurtEUR
22UAyTradeGateEUR
BNTXViennaEUR
Currency in USD
Disclaimer
86.17
-0.23(-0.27%)
Closed
Pre Market
85.84-0.33(-0.38%)

BNTX Comments

🔆🚀Pfizer and BioNTec Pfizer and BioNTech plan to submit a request for Emergency Use Authorization (EUA) of a booster dose for children ages 5 through 11 in the U.S. in the coming days. The companies also plan to share these data with the European Medicines Agency (EMA) and other regulatory agencies around the world as soon as possible.
BioNTech and Matinas BioPharma Announce Exclusive Research Collaboration to Evaluate Novel Delivery Technology for mRNA-based Vaccines
BNTX presented data from its ongoing first-in-human Phase 1/2 trial evaluating the safety and preliminary efficacy of the Company’s novel CAR-T cell therapy candidate, BNT211, in patients with advanced solid tumors. The preliminary results demonstrated an encouraging safety profile and anti-tumor activity in testicular cancer patients at the first evaluated dose levels of BNT211. The data were presented in the Clinical Trials Plenary Session at the AACR Annual Meeting 2022 by Prof. John Haanen, M.D., Ph.D., Netherlands Cancer Institute (NKI), Amsterdam, Netherlands.
🚀BNTX today announced that it is one of the companies in Germany to be granted a pandemic preparedness contract by the Federal Republic of Germany. The framework agreement is aimed at pandemic preparedness including manufacturing and supply of mRNA vaccines in emergency situations in Germany.🚀
🚀Profit taking from yesterday...will rebound.
‼️‼️Reuters Apr.4, WHO Covid warning: New mutant 'XE' Omicron variant could be most transmissible yet. It is highly contagious and could be much more transmissible than any other strain of COVID that we have ever encountered so far.
🔆🚀 BNTX today announced that it has entered into a share repurchase program (the “Program”), pursuant to which the Company may purchase American depositary shares (ADSs) in the amount of up to $1.5 billion over the next two years. BioNTech expects to use all or a portion of the ADSs to satisfy upcoming settlement obligations under the Company’s share-based payment arrangements.“We would like our shareholders to participate in our strong 2021 performance through a repurchase program of BioNTech shares. This is in line with our capital allocation strategy and our aim to continue to drive shareholder value,” said Jens Holstein, CFO of BioNTech.🚀
that was announced already yesterday, additional to the 2 bucks dividend, which is not even 1%. they should have increased the dividend and ho repurchase. buyback is just shrinking the balance sheet, throwing money out the window.
if pre market price will remain, 8% plus, it will really reflect the current valuation at below 200, even with this massive earnings, dividend and buyback. for people who bought at its peak, it translates to a 3 % gain. I think there will be little upside as to beat keep up this earnings in the future will be difficult. unless pre naked is wrong.
pre market 😀
Lol you have a drity mind! :D
just a bad auto correction
BioNTech SE is expected* to report earnings on 03/30/2022 before market open. The report will be for the fiscal Quarter ending Dec 2021. According to Zacks Investment Research, based on 6 analysts' forecasts, the consensus EPS forecast for the quarter is $8.02. The reported EPS for the same quarter last year was $1.87.BNTX has a "high" Earnings Quality Ranking (EQR) for the 2nd consecutive week. Earnings quality refers to the extent to which current earnings predict future earnings.Responder00
BNTX today announced that the U.S. Food and Drug Administration (FDA) has expanded the emergency use of their COVID-19 vaccine to include a second booster dose in adults ages 50 years and older who have previously received a first booster of any authorized COVID-19 vaccine. The FDA also has authorized a second booster dose for individuals 12 years of age and older who have been determined to have certain kinds of immunocompromise and who have received a first booster dose of any authorized COVID-19 vaccine. The additional booster is to be administered at least four months after the first booster and is the same formulation and strength as prior Pfizer-BioNTech COVID-19 vaccine doses.
NASDAQ and Friday sellers. Buy the dip.
The FDA has granted Breakthrough Therapy Designation to Pfizer BNTX Inc's respiratory syncytial virus (RSV) vaccine candidate (PF-06928316 or RSVpreF) to prevent lower respiratory tract disease caused by RSV in 60 years of age or older. The positive results primarily inform the FDA decision of Phase 2a study evaluating the safety, immunogenicity, and efficacy of a single dose of 120µg vaccine in a human viral challenge model in healthy adults 18 to 50 years of age.
1 week until Revenue Report. The numbers will be staggering. This is a staged dip, so buy now before the news!
thank you....
😄...
🔆🚀💲Get Ready...BNTX will announce its financial results for the full year and fourth quarter 2021 on Wednesday, March 30th, 2022. BioNTech invites investors and the general public to join a conference call and webcast with investment analysts on the same day at 8.00 a.m. EDT (2.00 p.m. CEST) to report its financial results and provide a corporate update for the fourth quarter and full year 2021. Can't wait to see the Revenue Report!💲
will be around 18 to 19b revenue. I do not think much surprises after PFE reg. Covid. all other pipelines, except combined covid shots,are still years away, there will not be any EUA there for cancer etc.
Patent infringement is bogus, will be dropped, and Alnylam said it does not intend to take action that impedes the production, sale or distribution of the BNTX and MRNA vaccines.
🚀🔆BNTX today announced the companies have submitted an application to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) of an additional booster dose adults 65 years of age and older who have received an initial booster of any of the authorized or approved COVID-19 vaccines. The submission is based on two real-world data sets from Israel analyzed at a time when the Omicron variant was widely circulating. Both data sets showed evidence that an additional mRNA booster increases immunogenicity and lowers rates of confirmed infections and severe illness🔆🚀
Profit taking from yesterday...will rebound.
...and thank you again....😂🙏...
:(
thank you Biontech for being such a crazy stock..😂😂😂🙏
Why spike?
Because of China cases
On way to All Time High...🚀
After this spike ..: bellow 100$ in one month
...
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.